Everest Organics Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 160546,
    "name": "Everest Organics",
    "stock_name": "Everest Organics",
    "full_name": "Everest Organics Ltd",
    "name_url": "stocks-analysis/everest-organics",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "416.00",
    "chg": 14.05,
    "chgp": "3.5%",
    "dir": 1,
    "prev_price": "401.95",
    "mcapval": "408.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524790,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE334C01029",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "283 ",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/everest-organics-160546-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Everest Organics Sees Revised Market Assessment Amid Mixed Financial Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/everest-organics-upgraded-from-sell-to-hold-by-marketsmojo-on-20-june-2025-3741382",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/EverestOrganics_mojoScore_3741382.png",
        "date": "2025-12-02 10:09:05",
        "description": "Everest Organics, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting a nuanced shift in its financial and technical outlook. This change comes amid a backdrop of mixed fundamental indicators and notable stock performance over the past year."
      },
      {
        "title": "Why is Everest Organics falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-everest-organics-fallingrising-3734230",
        "imagepath": "",
        "date": "2025-11-28 00:21:26",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Context</strong></p>\n<p>Everest Organics has experienced a notable pullback in the last week, with the stock declining by 9.87%, contrasting sharply with the Sensex's modest gain of 0.10% over the same period. This underperformance is significant given the stock's impressive year-to-date return of 37.17%, which outpaces the Sensex's 9.70% gain. Over the past year, Everest Organics has delivered an extraordinary 194.12% return, far exceeding the benchmark's 6.84%, underscoring its strong growth trajectory and investor interest in the longer term.</p>\n<p>Despite this robust historical performance, the recent five-day consecutive fall indicates a phase of profit-taking or short-term selling pressure. The stock's intraday low touched ₹405 on 27-Nov, representing ..."
      },
      {
        "title": "Is Everest Organics overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-everest-organics-overvalued-or-undervalued-3732438",
        "imagepath": "",
        "date": "2025-11-27 08:21:10",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Understanding Everest Organics’ Valuation Metrics</strong></p>\n<p>At present, Everest Organics trades at a price-to-earnings (PE) ratio of approximately 61, which is notably high compared to many of its industry peers. However, this elevated PE is tempered by a remarkably low price-to-earnings-growth (PEG) ratio of 0.30, suggesting that the company’s earnings growth prospects are robust relative to its price. The price-to-book value stands at 5.56, indicating that investors are willing to pay a premium over the company’s net asset value, a common trait in high-growth pharmaceutical firms.</p>\n<p>Enterprise value multiples such as EV to EBIT (41.22) and EV to EBITDA (26.52) also reflect a premium valuation, yet these figures must be contextualised within the company’s growth trajectory and pr..."
      },
      {
        "title": "Everest Organics Faces Intense Selling Pressure Amid Consecutive Losses",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/everest-organics-faces-intense-selling-pressure-amid-lower-circuit-lockdown-3725439",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/EverestOrganics_only_sellers_3725439.png",
        "date": "2025-11-24 12:10:10",
        "description": "Everest Organics Ltd has encountered significant selling pressure on 24 Nov 2025, with the stock registering a sharp decline and exhibiting a complete absence of buyers. The pharmaceutical and biotechnology company’s shares have fallen consecutively over the past two sessions, signalling distress selling and heightened market caution."
      },
      {
        "title": "Everest Organics Faces Intense Selling Pressure Amid Lower Circuit Lockdown",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/everest-organics-faces-severe-selling-pressure-hits-lower-circuit-amid-distress-signals-3721095",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/EverestOrganics_only_sellers_3721095.png",
        "date": "2025-11-21 13:40:09",
        "description": "Everest Organics Ltd experienced a pronounced sell-off on 21 Nov 2025, with the stock hitting its lower circuit and registering only sell orders in the queue. This extreme selling pressure signals distress among investors, as the pharmaceutical and biotechnology company’s shares declined sharply, diverging notably from broader market trends."
      },
      {
        "title": "Is Everest Organics overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-everest-organics-overvalued-or-undervalued-3709733",
        "imagepath": "",
        "date": "2025-11-18 08:20:12",
        "description": "As of 17 November 2025, the valuation grade for Everest Organics has moved from fair to expensive. The company is currently considered overvalued, with a PE ratio of 65.86, an EV to EBITDA ratio of 28.46, and a Price to Book Value of 6.01. These figures indicate that the stock is trading at a significant premium compared to its earnings and book value.\n\nIn comparison to its peers, Everest Organics' valuation stands out as particularly high; for instance, Sun Pharma has a PE ratio of 36.69, while Cipla is valued attractively with a PE of 22.81. The PEG ratio for Everest is also low at 0.32, suggesting that its growth prospects may not justify its current price. Notably, Everest Organics has outperformed the Sensex significantly in recent periods, with a year-to-date return of 49.14% compared to the Sensex's 8.72%...."
      },
      {
        "title": "Is Everest Organics overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-everest-organics-overvalued-or-undervalued-3705891",
        "imagepath": "",
        "date": "2025-11-17 08:07:41",
        "description": "As of 14 November 2025, Everest Organics has moved from an expensive valuation grade to fair. The company is currently fairly valued, with a PE ratio of 62.63, an EV to EBITDA ratio of 27.20, and a PEG ratio of 0.31. These ratios suggest that while the stock is priced higher than some peers, its growth potential is being recognized, especially given the low PEG ratio indicating potential undervaluation relative to growth.\n\nIn comparison to its peers, Everest Organics has a higher PE ratio than Sun Pharma (36.49) and a lower PEG ratio than Divi's Lab (1.97), which is categorized as very expensive. Notably, the company has demonstrated strong performance with a year-to-date return of 41.84%, significantly outpacing the Sensex return of 8.22% during the same period, reinforcing the notion that the stock may be fairly valued given its growth trajectory...."
      },
      {
        "title": "Is Everest Organics overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-everest-organics-overvalued-or-undervalued-3705198",
        "imagepath": "",
        "date": "2025-11-16 08:07:17",
        "description": "As of 14 November 2025, Everest Organics has moved from an expensive valuation grade to fair. The company is currently fairly valued, with a PE ratio of 62.63, an EV to EBITDA ratio of 27.20, and a PEG ratio of 0.31. In comparison to its peers, Sun Pharma has a PE ratio of 36.49 and an EV to EBITDA of 24.09, while Divi's Lab is significantly more expensive with a PE ratio of 69.65 and an EV to EBITDA of 52.35.\n\nDespite its high valuation ratios, Everest Organics shows a relatively attractive PEG ratio, indicating potential for growth compared to its price. The company's recent stock performance has outpaced the Sensex, with a year-to-date return of 41.84% compared to the Sensex's 8.22%, reinforcing the notion that it is fairly valued given its growth prospects in the pharmaceuticals and biotechnology sector...."
      },
      {
        "title": "Is Everest Organics overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-everest-organics-overvalued-or-undervalued-3704530",
        "imagepath": "",
        "date": "2025-11-15 08:07:48",
        "description": "As of 14 November 2025, Everest Organics has moved from an expensive to a fair valuation grade. The company is currently fairly valued based on its financial ratios, with a PE ratio of 62.63, an EV to EBITDA of 27.20, and a PEG ratio of 0.31. These ratios indicate that while the company has a high price-to-earnings ratio, its growth prospects may justify this valuation.\n\nIn comparison with peers, Everest Organics' PE ratio is significantly higher than that of Sun Pharma (36.49) and lower than Divi's Lab (69.65), which is categorized as very expensive. Additionally, its EV to EBITDA ratio is more favorable than that of Torrent Pharma (33.11), which is also very expensive. The recent performance of Everest Organics, with a year-to-date return of 41.84% compared to the Sensex's 8.22%, reinforces the notion that the stock is currently fairly valued in the market...."
      }
    ],
    "total": 309,
    "sid": "160546",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/everest-organics-160546"
  },
  "announcements": [
    {
      "caption": "Report On Re-Lodgement Of Transfer Request Of Physical Shares",
      "datetime": "22-Jan-2026",
      "details": "Report on re-lodgement of transfer request of physical shares.",
      "source": "BSE"
    },
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "17-Jan-2026",
      "details": "Certificate under SEBI ( Depositories and Participants) Regulations 2018.",
      "source": "BSE"
    },
    {
      "caption": "Closure of Trading Window",
      "datetime": "23-Dec-2025",
      "details": "Intimation for closure of trading window for the quarter ending December 31 2025.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Everest Organics Ltd has declared <strong>5%</strong> dividend, ex-date: 15 Sep 22",
          "dt": "2022-09-15",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Everest Organics Sees Revised Market Assessment Amid Mixed Financial Signals

2025-12-02 10:09:05

Everest Organics, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting a nuanced shift in its financial and technical outlook. This change comes amid a backdrop of mixed fundamental indicators and notable stock performance over the past year.

Why is Everest Organics falling/rising?

2025-11-28 00:21:26

Recent Price Movement and Market Context Everest Organics has experienced a notable pullback in the last week, with the stock declining by 9.87%, contrasting sharply with the Sensex's modest gain of 0.10% over the same period. This underperformance is significant given the stock's impressive year-to-date return of 37.17%, which outpaces the Sensex's 9.70% gain. Over the past year, Everest Organics has delivered an extraordinary 194.12% return, far exceeding the benchmark's 6.84%, underscoring its strong growth trajectory and investor interest in the longer term. Despite this robust historical performance, the recent five-day consecutive fall indicates a phase of profit-taking or short-term selling pressure. The stock's intraday low touched ₹405 on 27-Nov, representing ...

Is Everest Organics overvalued or undervalued?

2025-11-27 08:21:10

Understanding Everest Organics’ Valuation Metrics At present, Everest Organics trades at a price-to-earnings (PE) ratio of approximately 61, which is notably high compared to many of its industry peers. However, this elevated PE is tempered by a remarkably low price-to-earnings-growth (PEG) ratio of 0.30, suggesting that the company’s earnings growth prospects are robust relative to its price. The price-to-book value stands at 5.56, indicating that investors are willing to pay a premium over the company’s net asset value, a common trait in high-growth pharmaceutical firms. Enterprise value multiples such as EV to EBIT (41.22) and EV to EBITDA (26.52) also reflect a premium valuation, yet these figures must be contextualised within the company’s growth trajectory and pr...

Everest Organics Faces Intense Selling Pressure Amid Consecutive Losses

2025-11-24 12:10:10

Everest Organics Ltd has encountered significant selling pressure on 24 Nov 2025, with the stock registering a sharp decline and exhibiting a complete absence of buyers. The pharmaceutical and biotechnology company’s shares have fallen consecutively over the past two sessions, signalling distress selling and heightened market caution.

Everest Organics Faces Intense Selling Pressure Amid Lower Circuit Lockdown

2025-11-21 13:40:09

Everest Organics Ltd experienced a pronounced sell-off on 21 Nov 2025, with the stock hitting its lower circuit and registering only sell orders in the queue. This extreme selling pressure signals distress among investors, as the pharmaceutical and biotechnology company’s shares declined sharply, diverging notably from broader market trends.

Is Everest Organics overvalued or undervalued?

2025-11-18 08:20:12

As of 17 November 2025, the valuation grade for Everest Organics has moved from fair to expensive. The company is currently considered overvalued, with a PE ratio of 65.86, an EV to EBITDA ratio of 28.46, and a Price to Book Value of 6.01. These figures indicate that the stock is trading at a significant premium compared to its earnings and book value. In comparison to its peers, Everest Organics' valuation stands out as particularly high; for instance, Sun Pharma has a PE ratio of 36.69, while Cipla is valued attractively with a PE of 22.81. The PEG ratio for Everest is also low at 0.32, suggesting that its growth prospects may not justify its current price. Notably, Everest Organics has outperformed the Sensex significantly in recent periods, with a year-to-date return of 49.14% compared to the Sensex's 8.72%....

Is Everest Organics overvalued or undervalued?

2025-11-17 08:07:41

As of 14 November 2025, Everest Organics has moved from an expensive valuation grade to fair. The company is currently fairly valued, with a PE ratio of 62.63, an EV to EBITDA ratio of 27.20, and a PEG ratio of 0.31. These ratios suggest that while the stock is priced higher than some peers, its growth potential is being recognized, especially given the low PEG ratio indicating potential undervaluation relative to growth. In comparison to its peers, Everest Organics has a higher PE ratio than Sun Pharma (36.49) and a lower PEG ratio than Divi's Lab (1.97), which is categorized as very expensive. Notably, the company has demonstrated strong performance with a year-to-date return of 41.84%, significantly outpacing the Sensex return of 8.22% during the same period, reinforcing the notion that the stock may be fairly valued given its growth trajectory....

Is Everest Organics overvalued or undervalued?

2025-11-16 08:07:17

As of 14 November 2025, Everest Organics has moved from an expensive valuation grade to fair. The company is currently fairly valued, with a PE ratio of 62.63, an EV to EBITDA ratio of 27.20, and a PEG ratio of 0.31. In comparison to its peers, Sun Pharma has a PE ratio of 36.49 and an EV to EBITDA of 24.09, while Divi's Lab is significantly more expensive with a PE ratio of 69.65 and an EV to EBITDA of 52.35. Despite its high valuation ratios, Everest Organics shows a relatively attractive PEG ratio, indicating potential for growth compared to its price. The company's recent stock performance has outpaced the Sensex, with a year-to-date return of 41.84% compared to the Sensex's 8.22%, reinforcing the notion that it is fairly valued given its growth prospects in the pharmaceuticals and biotechnology sector....

Is Everest Organics overvalued or undervalued?

2025-11-15 08:07:48

As of 14 November 2025, Everest Organics has moved from an expensive to a fair valuation grade. The company is currently fairly valued based on its financial ratios, with a PE ratio of 62.63, an EV to EBITDA of 27.20, and a PEG ratio of 0.31. These ratios indicate that while the company has a high price-to-earnings ratio, its growth prospects may justify this valuation. In comparison with peers, Everest Organics' PE ratio is significantly higher than that of Sun Pharma (36.49) and lower than Divi's Lab (69.65), which is categorized as very expensive. Additionally, its EV to EBITDA ratio is more favorable than that of Torrent Pharma (33.11), which is also very expensive. The recent performance of Everest Organics, with a year-to-date return of 41.84% compared to the Sensex's 8.22%, reinforces the notion that the stock is currently fairly valued in the market....

View All News